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THE FIRST CLINICAL TRIALS of renal transplanta-
tion with cyclosporine therapy were reported four 
years ago by CaIne and associates (1, 2) who 
recommended from their experience that the drug 
should be used alone. In our own pilot trials (3,4), 
the alternative was developed of combining cyclo-
sporine with steroid therapy which was adminis-
tered in large doses on the day of the operation 
and rapidly reduced to relatively low maintenance 
levels. Although the results were encouraging, 
they were not conclusive since there were no pa-
tients for comparison who were treated during the 
same period with conventional immunosuppres-
sion. We report herein upon a second trial of cada-
veric renal transplantation, in which the results 
using cyclosporine-steroid therapy for primary 
cadaveric transplantation could be compared 
with those in patients treated contemporaneously 
with azathioprine and prednisone. Experience 
was also acquired with patients who underwent 
cadaveric retransplantation. 
METHODS 
Ninety-seven cadaveric renal homografts which. 
were obtained from brain dead donors were 
transplanted into 96 recipients in 1981. The 96 
recipients were placed into three general study 
groups (Table I) which were defined by two fac-
tors: the immunosuppressive therapy and a dis-
tinction between primary transplantation versus 
retransplantation. The three groups were com-
parable for recipient age, incidence of diabetes 
mellitus and prior transfusion history. Donor-
recipient matching at the A and B loci was poorest 
in those in group 1 who had primary grafts under 
cyclosporine and steroids (Table I). Dr typing 
data were incomplete and are not presented. 
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Among the 26 patients who underwent re-
transplantation (group 3), the sera of ten (38.5 
per cent) had warm anti-T lymphocyte cytotoxic 
antibodies which reacted against one-half or more 
of a lymphocyte panel contributed by 48 healthy 
donors. This condition was present only seven 
times (18 per cent) for primary transplantation 
under cyclosporine-steroids (group 1) and twice 
(6 per cent) for primary transplantation under 
azathioprine-prednisone (group 2). 
In nine of 96 recipients, T -warm antibodies 
were present which reacted against more than 90 
per cent of the panel (Table I). For five trans-
plantations--one in group 1, none in group 2 and 
four in group 3-there were T -warm antibodies 
in the recipient sera that had been collected as 
recently as three weeks earlier which completely 
killed the lymphocytes of the actual donor, al-
though cross matches were negative using sera 
drawn on the day of the operation. In most 
centers, such findings are construed as a positive 
cross match and preclude transplantation. 
Patients in groups 1 and 3 were given 17 milli-
grams per kilogram per day of cyclosporine on 
the day of the operation as well as a five day burst 
of prednisone which was begun at 200 milligrams 
in adults and reduced by daily decrements of 40 
milligrams in uncomplicated instances to a daily 
maintenance level of 20 milligrams. The details 
of therapy, the variability of convalescence, the 
indications for deviation from the original treat-
ment regimen and the need to distinguish be-
tween rejection and cyclosporine nephrotoxici-
ty in planning drug dose changes early or late 
after transplantation have been described else-
where (5). 
Azathioprine-prednisone therapy for primary 
cadaveric transplantations for those in group 2 
was with a formula that has been used in many 
centers, including this institution. for several 
years. Azathioprine was given in a dose of 5 milli-
grams per kilogram on the day of the operation 
and weaned to a plateau dose of 2 milligrams per 
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TABLE L-FEATURES OF 97 CONSECUTIVE CADAVERIC TRANSPLANTATIONS 
Age 
Total Total mean±S.D. Age 
Group patients grafts years <18 >55 
1, Cyc!osporine-steroids 
38 38 36.5±16.8 3 7 (primary) .... , .... 
2. Azathioprine-steroids 
32 39.4±14.6 7 (primary) ......... 32 4 
3, Cyclosporine-steroids 
26 27 31.3± 14.5 3 3 (retransplantation) .. 
kilogram per day within four days. This dosage 
was maintained unless bone marrow depression 
mandated a further reduction. Prednisone was 
started at 2 milligrams per kilogram per day with 
decrements of 0.25 milligrams per kilogram every 
five days until a daily maintenance dose of 0.4 
milligrams per kilogram per day was reached 
after 30 days in uncomplicated instances. Rejec-
tion was treated with augmented steroid dosages. 
The principal comparisons were between the 
primary cadaveric groups 1 and 2 in which 21 
and 20 patients, respectively, were part of a seven 
month randomized trial which was terminated 
prematurely because of the wide divergence of re-
sults. The complete patient material in groups 1 
and 2 included 17 and 12 additional patients, re-
spectively. Several of these extra patients were 
treated in 1981 just before or after the ran-
domized trial. Others specifically requested that 
one or the other type of immunosuppression be 
used after an informed consent briefing. A few 
could not participate in the randomized trail 
because they were minors. The results for the full 
groups 1 and 2 and the strictly randomized sub-
groups were analyzed separately. 
Because of the historically poor results with 
cadaveric retransplantation under conventional 
immunosuppression as reported by Husberg and 
Starzl (6) and Asher and co-workers (7), all pa-
tients in group 3 received cyclosporine-steroid 
therapy. The results for those in group 3 were 
compared with those after cadaveric retransplan-
tation during the preceding three years at this in-
stitution. Within group 3, comparisons were 
made between patients with and without widely 
reacting T -warm antibodies. 
RESULTS 
Patient Survival 
The one year mortality for the entire study 
was 2.1 per cent (two of 96). Both deaths were 
after primary transplantation. A 55 year old man 
with known coronary artery disease died of a 
myocardial infarction three weeks after primary 
transplantation under cyclosporine-steroid ther-
>50 per cent 
Patients A.B Antigen T-warm 
with type I 2: 3 previous matches antibodies in >YOpercent 
diabetes transfusions mean ± S.D. recipient sera antzbodzes 
6 26 0.79±0.9 7 2 
7 28 1.53±1,1 2 
25 1.46± 1.3 11 6 
apy; he had good renal function. A 43 year old 
woman in group 2 had rejection of the kidney 
within four months under azathioprine-steroid 
therapy and died of a gastrointestinal hemorrhage 
three months later after returning to chronic 
dialysis. An additional patient in group 1 died of 
a mid-gut infarction 17 months after transplanta-
tion. This 51 year old recipient had had a myo-
cardial infarction before transplantation and two 
more infarctions afterward. Renal function under 
cyclosporine and steroids was satisfactory until 
the time of death. 
The one year mortality after retransplantation 
was zero (group 3). However, a 41 year old man 
with a well functioning graft died of a ruptured 
abdominal aortic aneurysm 18 and one-half 
months postoperatively. After 15 to 27 months, 
92 of the 96 patients entered into the study were 
alive (95.8 per cent). 
Kidney Survival 
Group " (primary graft, cyclosporine-ste-
raids). Thirty-four of 38 kidneys (89.5 per cent) 
survived for one year and all but one that was lost 
by late death are still functioning after 15 to 24 
months (Fig. la). Only one of these patients has 
been switched to azathioprine. Nineteen of the 21 
kidneys (90.5 per cent) in the strictly randomized 
subgroup survived for one year and beyond; all 19 
grafts still function (Fig. 1 b). 
Group 2 (primary graft, azathioprine-ste-
roids). Sixteen of 32 grafts (50 per cent) survived 
for one year (Fig. la) but another kidney was lost 
to rejection after 13 months. Fifteen of the trans-
plants (47 per cent) are still functioning after 16 
to 26 months. Eleven of 20 grafts (55 per cent) in 
the strictly randomized subgroup functioned for 
at least one year, but one of these kidneys was 
rejected at 13 months (Fig. 1b). The results for 
those in the complete group 2 or its randomized 
subgroup were significantly poorer than for the 
comparable complete or partial group 1 (Fig. 1). 
Group 3 (retransplantation, cyclosporine-ste-
raids). The one year graft survival rate was 21 of 
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FIG. 1. a, The survival rate of kidneys after all primary cadaveric transplanta-
tions, in 1981, is shown. Follow-up studies were for at least 15 months. b, Results 
in randomized subset of 1981 experience, compared with the total results. Note that 
both the experimental (cyclosporine-steriods, 21 patients) and conventional (azath-
ioprine-steroids, 20 patients) randomized limbs were 3 per cent higher than in the 
total groups. 
antibodies against less than 50 per cent of the 
lymphocyte panel (Table II). The presence of 
more widely reacting antibodies had an adverse 
effect upon the results (Table II). Of the four pa-
tients in group 3 in whom stored preoperative 
sera contained antigraft antibodies, three had 
graft function of at least one year. 
chronic rejection after 13 and 15 months, and as 
the result of death after 18 and one-half months. 
The graft survival rate after 15 to 25 months is 18 
of 27 (66.7 per cent). None of the patients still 
bearing a graft has been changed to azathioprine. 
The results were twice as good as were achieved 
during the pre<;eding three years with azathio-
prine-steroid therapy (Fig. 2). 
The one year survival rate was 14 of 16 kid- Cause of Graft Losses 
neys (87.5 per cent) in group 3 which were trans- In group 1, three kidneys were lost to rejection 
planted to recipients in whom sera had T -warm and one from death (Table III). One of the rejec-
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TABLE n.-EFFECT OF T-WARM ANTIBODIES ON 
OUTCOME AFTER RETRANSPLANTATION UNDER 
CYCLOSPORINE-STERIODS 
No. oj One year 
grajts survival rate 
Antibodies < 50 per cent panel ......... . 16 14 (87.5) 
Antibodies > 50 per cent and < 90 per cent 
panel ............................ . 5 4 (80) 
Antibodies > 90 per cent panel ... . 6 3 (50) 
Total .............................. . 27 21 (77.8) 
Numbers in parentheses are percentages. 
tions was of the hyperacute variety after a blood 
typing error resulted in transplanting an A kid-
ney to an 0 recipient; another rejection occurred 
after an intestinal perforation necessitated discon-
tinuance of immunosuppression. Rejection under 
immunosuppression with azathioprine and ste-
roids caused the loss of 16 primary grafts in group 
2 (Table III). In spite of cyclosporine-steroid 
therapy, graft losses from acute or chronic rejec-
tion occurred five times after retransplantations 
in group 3 (Table II). 
RenaL Function 
The serum creatinine concentrations of pa-
tients still bearing functioning grafts are not 
demonstrably different in the three groups (Table 
IV). 
FinaL CycLosporine Dosages 
At the end of the first year, the patients in 
group 1 were receiving an average daily dose of 
5.2± 1.8 (S. D.) milligrams per kilogram and the 
recipients in group 3 received 5.8±2.0 (S. D.) 
milligrams per kilogram. The maintenance dos-
ages in both groups reflected the weaning that 
had been carried out, often in response to nephro-
toxicity. 
Steroid Consumption in Groups 1 and 2 
The culling process caused by the heavy loss of 
kidneys under conventional therapy made com-
parison of a steroid dosage decreasingly valid with 
time. However, the cumulative doses of predni-
sone during the first two months, in patients who 
had immunosuppression continued this long, was 
2.7 times greater in the recipients treated with 
azathioprine than in those who were given cyclo-
sporine (8). 
TABLE I11.-CAUSE OF GRAFT LOSS IN FIRST YEAR 
Rejection .................... . 
Technical complication ........ . 













.\ ABO mismatch; 1 after cessation of immunosuppression because of 
bowel perforation. and I despite standard drug administration. 
De Novo Malignant Disease 
In recipient groups 2 and 3, new tumors were 
not seen. Two patients in group 1 who received 
primary cadaveric homografts under cyclospor-
ine-steroid therapy had a neoplasm develop. One 
of the tumors was a polyclonal B-cell lymphoma 
in a 20 year old male who had evidence of an Ep-
stein-Barr virus infection. The lymphoma caused 
perforation of the ileum which was treated with 
an intestinal resection and a major reduction in 
cyclosporine and steroid dosages (5). The patient 
is well one and one-half years later with no 
evidence of persistent tumor and with normal 
renal function. 
The other neoplasm was a multifocal Kaposi 
sarcoma, mostly of the upper extremities but also 
involving the legs. The lesions appeared at the 
same time as increases occurred in cytomegalovi-
rus antibody titers. After the results of the biopsy 
confirmed the diagnosis, the patient was treated 
with a reduction of the cyclosporine dose from 10 
to 1.2 milligrams per kilogram per day as report-
ed by Little and co-workers (9). Over the ensuing 
13 months, the lesions disappeared completely 
while renal homograft function has remained ex-
cellent. There were no examples of new epithelial 
malignant growths in any of the groups. 
DISCUSSION 
Because of the low (2.1 per cent) one year pa-
tient mortality, assessment of the effectiveness of 
immunosuppression was almost free of the analyt-
ical artifact sometimes introduced by patient 
deaths despite satisfactory graft function. The 
survival rate of 89.5 per cent of the primary 
cadaveric grafts for one year and beyond using cy-
closporine-steroid therapy was possible in the ab-
sence of good tissue matches, without uniform 
recipient preparation with transfusions and with 
a mix of patients at low, intermediate and high 
risk. The one year primary cadaveric graft sur-
vival rate of 50 per cent in the control group using 
azathioprine-steroid therapy was the same as that 
in large multicenter compilations as reported by 
Opelz (10) and McDonald and co-workers (11), 
although this was slightly lower than obtained at 
our center during the previous two years. 
The direct comparison of cyclosporine-steroid 
immunosuppression with the conventional double 
drug combination of azathioprine and steroids 
has special practical importance because the lat-
ter therapy is, by far, the most widely used in the 
world today. Even when cyclosporine has been 
given alone, reserving steroids for the specific in-
dication of rejection, the results of European (12) 
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FIG. 2. The graft survival rate after cadaveric retransplantation under cyclospor-
ine-steroids compared with historical control groups. All follow-up studies are for 
at least 15 months. 
and Canadian (13) trials have shown an advan-
tage over azathioprine-steroid therapy. 
In another randomized trial at a single institu-
tion, Ferguson and co-workers (14) compared cy-
closporine-steroid therapy to triple drug therapy 
with azathioprine, prednisone and antilympho-
blast globulin (ALG). The graft survival in both 
groups was so high that differences were undetect-
able by this criterion. However, patients in the 
cyclosporine-steroid limb had fewer infections, 
fewer rejections, reduced steroid needs, shorter 
hospital stays and a smaller number of readmis-
sions. The triple drug regimen for patients in 
control groups has long been thought to provide 
improved immunosuppression as reported by 
Starzl and co-workers (15) and Najarian and as-
sociates (16), but difficulties with the expense, 
standardization, inconvenience, limited duration 
(because of sensitization) and the risk of ALG 
have restricted its use to a minority of centers. 
Nephrotoxicity, hepatotoxicity, hypertension, 
tremors, gum hyperplasia, hirsutism and flushing 
are side-effects of cyclosporine. All are relieved by 
dosage reduction, which may be guided by serial 
measurements of blood or plasma cyclosporine 
levels as shown by Kahan and associates (17). 
However, management with clinical criteria is 
relatively easy. The most important practical 
problems in renal recipients are the differentia-
tion of rejection from nephrotoxicity as reported 
by CaIne and co-workers (2, 18), and Starzl and 
associates (3, 4, 5). 
In the first clinical trials with cyclosporine as 
reported by CaIne and co-workers (2), almost 10 
per cent of the patients had lymphomas develop. 
In a subsequent experience reported by Bird (19), 
the incidence of lymphomas under cyclosporine 
or cyclosporine-steroid therapy has been little 
different than with conventional immunosuppres-
sion, and almost all have been associated with 
Epstein-Barr virus infections. Much remains to 
be learned of the behavior of these lesions which, 
in the world experience with cyclosporine, have 
not been responsible for the death of any renal 
recipient as noted by Penn (20). Our approach to 
therapy has been to reduce drastically the dosages 
of both cyclosporine and steroids and to excise the 
tumor if possible (4, 5). In patients treated with 
azathiopine, prednisone and ALG, the disap-
pearance of lymphoma-like neoplasms after dis-
continuance of immunosuppression has been 
described (21). The same principle probably ap-
plies to the therapy of other neoplasms that have 
been associated with viruses. For example, a mul-
ticentric Kaposi's sarcoma in one of our patients 
treated with cyclosporine disappeared after major 
dosage reductions. There has been a singular ab-
TABLE IV.-SERUM CREATININE LEVELS (MGM PER 
CENT) (AFTER 15 TO 27 MONTHS) 
Group 1 Group 2 Group 3 
No. functioning .......... 33/38 15/32 18/27 
No. creatinine < 3.0 mgm. 
per cent .............. 32 15 18 
No. creatinine ~ 3.0 mgm. 
per cent .............. 0 0 
Mean ± S.D. mgm. per cent 
all patients ............ 1.97±0.50 1.61±0.60 t.92±0.54 
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sence in patients treated with cyclosporine of 
epithelial neoplasms which account for 75 per 
cent of the malignant diseases under conventional 
immunosuppression as reported in a study by 
Penn (22). 
The results of late follow-up study of patients 
treated with cydosporine in the pilot trials of 
1978 to 1980 have shown that the drug can be ad-
ministered chronically as reported by CaIne and 
associates (18) and Starzl and co-workers (23). 
Unusual late complications have not been seen, 
providing that the daily cyclosporine dosages are 
slowly reduced with the passage of time. 
The impact of cyclosporine-steroid therapy 
upon transplantation policies and End Stage 
Renal Disease programs should be major. The 
ability to carry out cadaveric transplantation 
safely, effectively and with low maintenance ster-
oid doses may limit or make obsolete the use of 
living related donors. More patients considered at 
high risk because of age, diabetes mellitus or 
other factors could be considered for transplanta-
tion candidacy. Public education to increase sup-
port of cadaveric donor procurement will be a 
corollary. With the realization that retransplan-
tation can be successful, the temptation for over 
immunosuppression will be lessened and the 
mortality should decline. Tissue typing, which 
has never been a precise instrument for donor-
recipient matching in cadaveric transplantation 
as reported by Opelz and co-workers (10) and 
McDonald and associates (11), will become even 
less important. Conversely, detection of presensi-
tization states, including those signaled by cyto-
toxic antibodies, will be more important. Deliber-
ate blood transfusions, in preparation for trans-
plantation to improve graft survival, will become 
less prevalent since the penalty of sensitizing a 
significant number of potential recipients and 
rendering them nontransplantable will not be 
necessary. Finally, the interface between dialysis 
and transplantation will be changed. With more 
patients seeking the greater rehabilitation that is 
offered by transplantation, the mounting costs of 
the End Stage Renal Disease program should be 
reduced. 
SUMMARY 
Ninety-seven cadaveric renal transplants were 
performed upon 96 patients during 1981. The 
one year patient mortality was 2.1 per cent. 
Seventy of the recipients were undergoing trans-
plantation for the first time. Of these patients, 38 
were treated with cyclosporine and steroids with 
a one year graft survival rate of 89.5 per cent. 
The other 32 primary recIpients were treated 
with azathioprine and steroids with a one year 
graft survival rate of 50 per cent. The difference 
between the cyclosporine-steroid versus conven-
tional therapy groups was significant. Cyclospor-
ine and steroids also were used to treat 26 patients 
who underwent retransplantation with 27 cadav-
eric grafts. The one year graft survival time was 
77.8 per cent; most of the graft losses were in pre-
sensitized patients. The results with retransplan-
tation were twice as good as in historical control 
groups. 
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